Oculis Secures FDA Breakthrough Therapy Designation For Privosegtor In Optic Neuritis As PIONEER Program Targets $7B US Neuroprotective Market
Benzinga Newsdesk 10 months ago
News
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies,
- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis
- Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S.
- Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial